medicated intrauterine devices
Summary: Intrauterine devices that release contraceptive agents.
Publications164 found, 100 shown here
- Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagiaA Kriplani
Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
Int J Gynaecol Obstet 97:190-4. 2007..To evaluate the efficacy, acceptability, and possible side effects of a levonorgestrel-releasing intrauterine system for menorrhagia...
- Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagiaJulian W Barrington
Department of Obstetrics and Gynaecology, Torbay Hospital, Torquay, Devon, UK
Eur J Obstet Gynecol Reprod Biol 108:72-4. 2003..To compare the effectiveness of endometrial thermal ablation and the levonorgestrel intrauterine system (LNG-IUS) in the management of menorrhagia...
- Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagiaRobert W Shaw
Academic Division of Obstetrics and Gynaecology, University of Nottingham, Derby, UK
Aust N Z J Obstet Gynaecol 47:335-40. 2007....
- Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized studyWing Hung Tam
Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, SAR, China
Gynecol Obstet Invest 62:84-8. 2006..To compare patients' health status function after treatment with thermal balloon endometrial ablation (TBEA) and levonorgestrel intrauterine system (LNG-IUS) for idiopathic menorrhagia...
- Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-upRitva Hurskainen
Department of Obstetrics and Gynecology, University of Helsinki, Finland
JAMA 291:1456-63. 2004..Both the levonorgestrel-releasing intrauterine system (LNG-IUS) and hysterectomy have proven effective for treatment of menorrhagia but there are no long-term comparative studies measuring cost and quality of life...
- Endometrial effects of intrauterine levonorgestrelAnja Guttinger
Division of Reproductive and Developmental Sciences, The Queen s Medical Research Institute, Centre for Reproductive Biology, The University of Edinburgh, EH16 4TJ Edinburgh, UK
Contraception 75:S93-8. 2007..Much remains to be determined about the mechanisms involved in suppression of menstruation, BTB episodes and the local endometrial environment with local LNG administration...
- Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometriumKevin A Burton
Centre for Reproductive Biology, Chancellor s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
Hum Reprod 18:2610-7. 2003....
- Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifenM D Kesim
Sisli Etfal Research and Training Hospital, 3th Obstetrics and Gynecology Clinic, Istanbul, Turkey
Climacteric 11:252-7. 2008..To investigate the long-term effects of a levonorgestrel-releasing intrauterine system on the endometrium and lipid profile of breast cancer patients taking tamoxifen...
- Update on treatment of menstrual disordersDavid H Eizenberg
Med J Aust 179:454-5; author reply 455. 2003
- Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New ZealandMira Harrison-Woolrych
Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
N Z Med J 116:U538. 2003..To compare the incidence of reported insertion problems with the levonorgestrel-releasing intrauterine device (Mirena) with that of the copper device Multiload Cu 375...
- Re: The use of levonorgestrel-releasing intrauterine system for the treatment of menorrhagia in women with inherited bleeding disordersRebecca Curtis
BJOG 113:248-9. 2006
- The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometriumB A Roopa
Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore, Singapore
Hum Reprod 18:1809-19. 2003....
- Use of the levonorgestrel-IUD in the treatment of menorrhagia: improving patient outcomes while reducing the need for surgical managementAndrew M Kaunitz
Department of Obstetrics and Gynecology, University of Florida Health Science Center, Jacksonville, Florida, USA
Manag Care Interface 20:47-50. 2007..In particular, the levonorgestrel-releasing intrauterine system (LNG-IUS), a nonsurgical, reversible treatment, provides effective management for many women with menorrhagia while minimizing morbidity and health care costs...
- The effect of the levonorgestrel intrauterine system on uterine artery blood flow 1 year after insertionA Haberal
Department of Gynecology, S S K Ankara Maternity and Women s Health Teaching Hospital, Ankara, Turkey
Ultrasound Obstet Gynecol 27:316-9. 2006..To assess whether the morphological alterations of the endometrium induced by the levonorgestrel intrauterine system affect the uterine artery vasculature...
- The Mirena levonorgestrel systemC Jay McGavigan
Department of Obstetrics and Gynecology, Southern General Hospital, South Glasgow University Hospitals NHS Trust, Govan, Glasgow, UK
Drugs Today (Barc) 39:973-84. 2003..Detailed counseling is crucial to explain this anticipated side effect in order to reduce unnecessary discontinuation of treatment...
- Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokersT Kucuk
Department of Obstetrics and Gynecology, GATA School of Medicine, Ankara, Turkey
Clin Exp Obstet Gynecol 35:57-60. 2008..To compare the efficacy of three progestin regimens in perimenopausal menorrhagia...
- Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine systemDirk Wildemeersch
Contrel Research, Technology Park 3, 9052 Zwijnaarde, Ghent, Belgium
Contraception 71:470-3. 2005..The daily release of the LNG IUS was approximately 20 mug...
- Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imagingAristides M Bragheto
Human Reproduction Unit, Department of Obstetrics and Gynecology, Campinas, 13084 971 SP, Brazil
Contraception 76:195-9. 2007..This study was conducted to evaluate the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on adenomyotic lesions diagnosed and monitored by magnetic resonance imaging (MRI)...
- Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment chartsPeter C Reid
Luton and Dunstable NHS Trust, Luton, UK
BJOG 112:1121-5. 2005..To compare the efficacy and tolerability of the levonorgestrel intrauterine system (LNG IUS) with mefenamic acid in the management of objective idiopathic menorrhagia...
- The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disordersMay Wahab
BJOG 112:1455-6. 2005
- The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disordersC E C Kingman
Department of Obstetrics and Gynaecology, Royal Free Hospital, London, UK
BJOG 111:1425-8. 2004..The levonorgestrel-releasing intrauterine system (LNG-IUS) is used commonly by gynaecologists as a contraceptive and to treat menorrhagia. However, its efficacy has not been examined in women with inherited bleeding disorders...
- Levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleedingRitva Hurskainen
Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, PL 140, 0029 HUS, Helsinki, Finland
Curr Opin Obstet Gynecol 16:487-90. 2004..The levonorgestrel-releasing intrauterine system is an effective medical treatment for menorrhagia. Emerging clinical and research evidence suggests that this new treatment modality has major health benefits...
- Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosisMoamar Al-Jefout
Department of Obstetrics and Gynaecology, Queen Elizabeth II Research Institute for Mothers and Infants, University of Sydney, New South Wales, Australia
Aust N Z J Obstet Gynaecol 47:247-9. 2007....
- Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine systemDiana Mansour
Graingerville Clinic, Newcastle General Hospital, Newcastle upon Tyne, UK
Best Pract Res Clin Obstet Gynaecol 21:1007-21. 2007..This article will outline the development of the IUS, highlighting the most important recent areas of research covering its use to control menstrual blood loss and pain...
- Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasiaXiujuan Qi
Department of Obstetrics and Gynecology, Qingdao University Medical School, Qingdao, PR China
Gynecol Obstet Invest 65:266-8. 2008..Histological morphology of endometrial samples after 6 months' exposure to LNG-IUS showed secretory or atrophic glands with decidualized stroma. Two healthy babies were born following ovulation induction after removal of the LNG-IUS...
- Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomasTakeshi Maruo
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, 650 0017, Japan
Contraception 75:S99-103. 2007..The cell type-specific action of CDB2914 on leiomyoma cells, without affecting the surrounding normal myometrial cells, is meaningful for understanding the usefulness of CDB2914 in the medical treatment of uterine myomas...
- Levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of essential menorrhagia: predictors of outcomeRitva Hurskainen
Departments of Obstetrics and Gynecology, University Hospitals of Helsinki, Finland
Acta Obstet Gynecol Scand 83:401-3. 2004..However, the treatment with LNG-IUS seemed to be an appropriate alternative to hysterectomy for all women who perceived their MBL heavy...
- Menorrhagia, mechanisms and targeted therapiesJulia Osei
Reproductive and Developmental Sciences Obstetrics and Gynaecology, Centre for Reproductive Biology, University of Edinburgh, Edinburgh, UK
Curr Opin Obstet Gynecol 17:411-8. 2005..This review summarizes recent developments in the nonsurgical approach to treating menorrhagia...
- A retrospective cohort study comparing microwave endometrial ablation with levonorgestrel-releasing intrauterine device in the management of heavy menstrual bleedingRichard Henshaw
South East Regional Health Service, Adelaide, South Australia, Australia
Aust N Z J Obstet Gynaecol 42:205-9. 2002..To compare microwave endometrial ablation (MEA) with a levonorgestrel-releasing intrauterine device (Mirena) in the management of heavy menstrual bleeding...
- Experience with the levonorgestrel-releasing intrauterine system among HIV-infected womenPäivi Lehtovirta
Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 Helsinki, Finland
Contraception 75:37-9. 2007..Yet, little is known about LNG-IUS use in HIV-infected women...
- Progestin-releasing intrauterine systemsT Luukkainen
Steroid Research Laboratory, Institute of Biomedicine, University of Helsinki, Helsinki, Finland
Semin Reprod Med 19:355-63. 2001..Users should be told that the LNG IUS does not prevent sexually transmitted infection, and therefore women at risk should also use condoms for their protection...
- Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot studyD Wildemeersch
Contrel Research, Technology Park Zwijnaarde, Ghent, Belgium
Contraception 66:93-9. 2002....
- The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosisAna Carolina Japur de Sa Rosa E Silva
Department of Obstetrics and Gynecology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
Fertil Steril 86:742-4. 2006..The levonorgestrel-releasing intrauterine device was found to be as efficient as GnRH agonist in reducing CA-125 serum levels...
- Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapyRezan A Kadir
Department of Obstetrics and Gynaecology and Katharine Dormandy Haemophilia Center and Haemostasis Unit, Royal Free Hospital, NW3 2QG London, UK
Contraception 75:S123-9. 2007..Proper counselling remains crucial for patients' satisfaction...
- [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil]Daniela Angerame Yela
Departamento de Obstetricia e Ginecologia, Faculdade de Medicina, Universidade Estadual de Campinas UNICAMP, Campinas, Brazil
Rev Assoc Med Bras 52:32-6. 2006....
- The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in womenNaomi B Morison
Prince Henry s Institute, PO Box 5152, Clayton, Victoria, Australia
Reproduction 133:309-21. 2007..MMP7 was primarily associated with tissue repair. Therefore, this model mimics some of the changes observed in endometria of women using p-only contraceptives and provides an opportunity for functional studies...
- The local progestational effect of the levonorgestrel-releasing intrauterine system: a sonographic and Doppler flow studyY Zalel
Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel
Hum Reprod 17:2878-80. 2002..We aimed to evaluate the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on the uterine vasculature and the endometrium...
- The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphologyV Phillips
Department of Pathology, Royal Group of Hospitals Trust, Grosvenor Road, Belfast BT12 6BL, Northern Ireland, UK
J Clin Pathol 56:305-7. 2003..The Mirena coil is a levonorgestrel releasing intrauterine device that is in widespread use. This study aims to document the endometrial morphology associated with this device...
- A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleedingR A Busfield
Department of Obstetrics and Gynaecology, National Women s Hospital, University of Auckland, Auckland, New Zealand
BJOG 113:257-63. 2006..To compare the levonorgestrel intrauterine system (LNG-IUS) (Mirena); Schering Co., Turku, Finland) and thermal balloon ablation (Thermachoice; Gynecare Inc., Menlo Park, CA, USA) for the treatment of heavy menstrual bleeding...
- The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trialK Halmesmäki
Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
BJOG 114:563-8. 2007..To compare among women with menorrhagia the effect of hysterectomy or levonorgestrel-releasing intrauterine system (LNG-IUS) on sexual functioning...
- Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up studyErika Baldaszti
Ludwig Boltzmann Institute for Womens Health Research, A 1180, Vienna, Bastiengasse 36 38, Austria
Contraception 67:87-91. 2003..LNG-IUS is a well-accepted contraceptive method, without negative influences on the sexual relationship between users and their partners, and is suitable for women requiring long-term reversible contraceptive protection...
- Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomasJarbas Magalhães
Department of Obstetrics and Gynecology, Clinic of Gynecological Endocrinology, School of Medicine, Santa Casa de Sao Paulo, São Paulo 01221 900, Brazil
Contraception 75:193-8. 2007..A control group used the device as a contraceptive method (n=28)...
- Revisiting the intrauterine contraceptive device in adolescentsAlina Toma
Department of Obstetrics and Gynaecology, Queen s University, Kingston, Ontario, Canada
J Pediatr Adolesc Gynecol 19:291-6. 2006....
- Medical and surgical management of adenomyosisCynthia Farquhar
Department of Obstetrics and Gynaecology, National Womens Health at Auckland, City Hospital, University of Auckland, Private Bag 92019, Auckland, New Zealand
Best Pract Res Clin Obstet Gynaecol 20:603-16. 2006..Hysterectomy or use of the levonorgestrel intrauterine system (LNG-IUS) remains the mainstay of treatment...
- Hormonal contraception and risk of venous thromboembolism: national follow-up studyØjvind Lidegaard
Gynaecological Clinic, Rigshospitalet, Copenhagen University, DK 2100 Copenhagen, Denmark
BMJ 339:b2890. 2009..To assess the risk of venous thrombosis in current users of different types of hormonal contraception, focusing on regimen, oestrogen dose, type of progestogen, and route of administration...
- Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implantsIrving Sivin
Population Council, Center for Biomedical Research, New York, New York 10021, USA
Drug Saf 26:303-35. 2003..and pelvic inflammatory disease are reduced in comparison with those of women using copper or non-medicated intrauterine devices. Risks of developing gallbladder disease and hypertension or borderline hypertension, although small, ..
- Neoplasia with use of intrauterine devicesKathryn M Curtis
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
Contraception 75:S60-9. 2007..Additionally, hormone-releasing IUDs or intrauterine systems (IUSs) release progestins or progesterone into the uterus. Both of these mechanisms may affect users' risk for neoplasia...
- Advances in uterine protein research: reproduction and cancerM Seppala
Department of Obstetrics and Gynecology, Clinical Chemistry, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
Int J Gynaecol Obstet 85:105-18. 2004..Research on functional glycomics continues to produce significant information on fundamental aspects of fertilization, implantation, pregnancy and cancer...
- The levonorgestrel-releasing intrauterine system in modern gynaecologyC Jay McGavigan
Department of Gynaecology, Glasgow Royal Infirmary, Glasgow G4 0SF
Br J Hosp Med (Lond) 66:574-7. 2005..Compliance can sometimes be hampered by troublesome side effects (principally breakthrough bleeding) but appropriate counselling can reduce unnecessary discontinuation...
- Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overviewRajesh Varma
Academic Department of Obstetrics and Gynaecology, Birmingham Women s Hospital, Birmingham B15 2TG, UK
Eur J Obstet Gynecol Reprod Biol 125:9-28. 2006..This systematic enquiry and overview evaluates the quality of evidence relating to the non-contraceptive therapeutic uses of LNG-IUS in gynaecology...
- Long-term use of the levonorgestrel-releasing intrauterine systemPirjo Inki
Bayer Schering Pharma AG, D 13342 Berlin, Germany
Contraception 75:S161-6. 2007..g., oral progestins). Use of the LNG IUS in combination with estrogen therapy in women undergoing menopausal transition seems to be well tolerated and associated with a favorable bleeding pattern...
- Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleedingB Gupta
Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
Int J Gynaecol Obstet 95:261-6. 2006..To compare the acceptability, efficacy, adverse effects, and user satisfaction of a levonorgestrel intrauterine system (LNG-IUS) and transcervical resection of the endometrium (TCRE) for the treatment of dysfunctional uterine bleeding...
- Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms--a reviewYoav Peled
Helen Schneider Women s Hospital, Rabin Medical Center, Beilinston Campus, Petah Tiqwa, Israel
Menopause 14:550-4. 2007..In this article we review the findings on the use of the novel levonorgestrel-releasing intrauterine system as a therapeutic tool for localized, rather than systemic, progesterone administration in postmenopausal women...
- Pseudo-decidual reaction to Mirena coil in a cervical smear: a potential diagnostic pitfall for false-positive cervical cytologyC Hughes
Cytopathology 16:268-9. 2005
- The intrauterine device: rethinking old paradigmsKatherine W Morgan
University of Utah College of Nursing, 10 South 2000 East, Salt Lake City, UT 84112, USA
J Midwifery Womens Health 51:464-70. 2006..In light of this data, the IUD should be made available to women at low-risk for sexually-transmitted infections and should not be denied to women on the basis of parity or marital status...
- Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing devicePaivi Pakarinen
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, 00029 HUS Helsinki, Finland
Contraception 72:342-5. 2005..A randomized study was performed to compare the efficacy, safety and acceptability of a new model of an intracervical/intrauterine contraceptive device (ICD) releasing 20 microg of levonorgestrel (LNG) per day...
- [Levonorgestrel-releasing intrauterine system for treatment of dysmenorrhea associated with adenomyosis]Jie Sheng
Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China
Zhonghua Fu Chan Ke Za Zhi 41:467-70. 2006..To evaluate the efficacy and safety of a levonorgestrel-releasing intrauterine system (LNG-IUS) for the treatment of dysmenorrhea associated with adenomyosis...
- Primary ovarian pregnancy with a levonorgestrel intrauterine systemEmmanuel Kalu
Assisted Conception Unit, St Helier Hospital, Carshalton, UK
J Fam Plann Reprod Health Care 32:253-4. 2006
- Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian SurveySidsel Graff-Iversen
National Health Screening Service, Oslo, Norway
Contraception 66:7-13. 2002..Use of the IUD with levonorgestrel was also linked with a decreased risk of high serum triglycerides and of high non-HDL-cholesterol concentrations and a total/HDL-cholesterol ratio similar to that of nonusers of hormones...
- Exacerbation of Crohn's disease after insertion of a levonorgestrel intrauterine system: a case reportJacqueline Wakeman
Langton Medical Group, St Chad Health Centre, Lichfield, UK
J Fam Plann Reprod Health Care 29:154. 2003....
- Levonorgestrel-releasing intrauterine system and new-onset acneJordan R Ilse
Cutis 82:158. 2008
- Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosisJ B Laoag-Fernandez
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan
Hum Reprod 18:694-9. 2003..Endometrial angiogenesis is believed to be regulated by angiogenic factors. The study aim was to evaluate the effects of LNg-IUS on vascular endothelial growth factor (VEGF) and adrenomedullin (AM) expression in the endometrium...
- Levonorgestrel intrauterine system: a first-line medical treatment for heavy menstrual bleedingAnita L Nelson
David Geffen School of Medicine at UCLA, Torrance, CA, USA
Womens Health (Lond Engl) 6:347-56. 2010....
- Ectopic pregnancy risk when contraception fails. A reviewLesley Anne Furlong
U S Food and Drug Administration, HFD 580, 5600 Fishers Lane, Rockville, MD 20857, USA
J Reprod Med 47:881-5. 2002..To alert clinicians to the risk of ectopic pregnancy when certain contraceptive methods fail by summarizing data from trials reviewed by the U.S. Food and Drug Administration (FDA)...
- Can the levonorgestrel intrauterine system replace surgical treatment for the management of menorrhagia?Rani Nagrani
Department of Obstetrics and Gynaecology, Singleton Hospital, Swansea, UK
BJOG 109:345-7. 2002..4% avoided surgery. The LNG-IUS is well accepted and effective in the management of menorrhagia and has major cost implications to the National Health Service...
- Ectopic pregnancy with a translocated Mirena intrauterine systemFook Ng Kee Kwong
Leicester Royal Infirmary NHS Trust, Leicester, UK
J Fam Plann Reprod Health Care 28:95-6. 2002..The IUS was removed laparoscopically. This is likely to be the first reported case of a simultaneous ectopic pregnancy and an extrauterine system. It is not clear whether removal of the Mirena IUS was necessary...
- Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogueRodrigo Alves Ferreira
Department of Obstetrics and Gynecology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto, SP, 14049 900, Brazil
Contraception 81:117-22. 2010....
- Fertility and endocrine effects of intra-abdominally misplaced intrauterine system for more than 2 years: a case report and review of the literatureGeorge Botros
Countess of Chester, O and G, Chester, UK
Hum Fertil (Camb) 12:119-21. 2009..Intraabdominal misplacement of the LNG-IUS has been reported in the literature with variable consequences and effects. In this case report, we reviewed the literature and assessed the fertility and endocrine consequences...
- [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)]F Imperato
II Facolta di Medicina e Chirurgia, Istituto di Ostetricia e Ginecologia, Universita degli Studi La Sapienza, Rome, Italy
Minerva Ginecol 54:271-8. 2002..The authors evaluated the effect of copper surface area on uterine bleeding...
- Pregnancy during the use of levonorgestrel intrauterine systemTiina Backman
Department of Obstetrics and Gynecology, University Hospital of Turku, Finland
Am J Obstet Gynecol 190:50-4. 2004..This study was undertaken to evaluate the pregnancy rate with the levonorgestrel intrauterine system (LNG IUS) and to analyze the outcome of pregnancies with the LNG IUS in situ in regular use...
- The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfactionI Lete
Santiago Apostol Hospital, Vitoria, Alava, Spain
Eur J Contracept Reprod Health Care 13:231-7. 2008..To evaluate patient satisfaction and improvement in quality of life (QoL) among women with idiopathic menorrhagia treated with the levonorgestrel intrauterine system (LNG-IUS)...
- Cervical cytological studies in women inserted with Norplant-I contraceptiveJata S Misra
Human Reproduction Research Centre, Department of Obstetrics and Gynaecology, C S M Medical University, Lucknow, India
Diagn Cytopathol 29:136-9. 2003..The accumulated data indicate the safety of long-term use of Norplants upto 5 yr, as far as oncogenic potential is concerned...
- [Extrauterine pregnancy with gestagen-releasing intrauterine device in situ]Mette Schou Mikkelsen
Regionshospitalet Randers, gynaekologisk obstetrisk afdeling, Denmark
Ugeskr Laeger 172:1304-5. 2010..We describe one of these rare cases of ectopic pregnancy in a woman aged 37 years, who was admitted to hospital with abdominal pain and vaginal bleeding...
- Viable cervical pregnancy with levonorgestrel containing intrauterine device, treated successfully with methotrexate and mifepristoneIngrid De Greef
Eur J Obstet Gynecol Reprod Biol 120:233-5. 2005
- Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrelR Hurskainen
Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, PO Box 140, Helsinki, Finland
Mol Hum Reprod 6:1013-8. 2000..No significant differences were found in the parameters studied between the women with and without breakthrough bleeding 6 months after insertion of an LNG-IUS...
- Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine systemOskari Heikinheimo
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
Contraception 81:481-6. 2010..Misoprostol has been studied intensively to produce cervical dilatation. To date, no studies have evaluated the effectiveness, safety or acceptability of this treatment for repeat intrauterine device insertions...
- The future of hysterectomyRay Garry
University of Western Australia, King Edward Memorial Hospital, Subiaco, Western Australia, Australia
BJOG 112:133-9. 2005
- Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of timeSoraya Labied
Groupe Interdisciplinaire de Génoprotéomique Appliquée GIGA R, Laboratory of Tumor and Development Biology, Centre de Recherche en cancérologie Expérimentale, University of Liege, Tour de Pathologie B23, Sart Tilman, B 4000 Liege, Belgium
Hum Reprod 24:113-21. 2009..Thus the objective of this study was to compare matrix metalloproteinase (MMP) expression in endometrium during luteal phase and in short-term (1 month) and long-term (> or =6 months) LNG-IUS users...
- The levonorgestrel-releasing intrauterine system: an updated review of the contraceptive and noncontraceptive usesCamaryn Chrisman
Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Clin Obstet Gynecol 50:886-97. 2007..In addition to its contraceptive effect, the levonorgestrel intrauterine system offers potential therapeutic benefits in other clinical contexts, including menorrhagia, symptomatic fibroids, endometriosis, and endometrial suppression...
- Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disordersAndrea S Lukes
Carolina Women s Research and Wellness Center, Chapel Hill, North Carolina 27514, USA
Fertil Steril 90:673-7. 2008..To evaluate the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in women with known hemostatic disorders and abnormal uterine bleeding...
- Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine systemAlessandra Peloggia
Human Reproduction Unit, Department of Obstetrics and Gynaecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, Campinas, SP, Brazil
Hum Reprod 21:1129-34. 2006..The objective was to assess endometrial chemokines in users of the levonorgestrel-releasing intrauterine system (LNG-IUS) and correlate them with leucocyte populations, uterine natural killer cells (uNK) and mast cells (MCs)...
- The effect of the levonorgestrel-releasing intrauterine system and the copper intrauterine device on subendometrial microvascularization and uterine artery blood flowMirela Foresti Jiménez
Faculdade de Medicina, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
Fertil Steril 90:1574-8. 2008..To evaluate the effect of the levonorgestrel intrauterine system (LNG-IUS) and TCU 380A on the subendometrial vascularization and the uterine artery blood flow during the midluteal phase...
- Safety of a progesterone-releasing intravaginal device as assessed from vaginal mucosal integrity and indicators of systemic inflammation in postpartum dairy cowsRobert B Walsh
Department of Population Medicine, University of Guelph, Guelph, Ontario N1G 2W1
Can J Vet Res 72:43-9. 2008..There was no significant difference in the circulating haptoglobin concentration between the 3 groups of cows. Culture revealed commensal bacterial growth in the vagina of all the cows...
- A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptomsK Halmesmäki
Department of Obstetrics and Gynecology, Central Hospital of Päijät Häme, Keskussairaalankatu 7, 15850 Lahti, Finland
Hum Reprod 19:378-82. 2004..The purpose of this study was to compare the effects of hysterectomy and a levonorgestrel-releasing intrauterine system (LNG-IUS) on serum FSH levels and menopausal symptoms...
- Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general populationLaure Morin-Papunen
Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland
Am J Obstet Gynecol 199:529.e1-529.e10. 2008..We compared the metabolic and cardiovascular parameters of a reference group of women with those of women who used 2 contraceptive regimes that are used worldwide: the levonorgestrel-releasing intrauterine device and oral contraceptives...
- [A levonorgestrel-containing IUD for the treatment of endometriosis]E Stekkinger
Deventer Ziekenhuis, Afd Gynaecologie, Verloskunde en Voortplantings geneeskunde, Postbus 5001, 7400 GC Deventer
Ned Tijdschr Geneeskd 151:2372-6. 2007..However, the level of evidence of these studies is lower than that of the standard hormonal treatment options, since large randomised controlled trials are still lacking...
- The use of levonorgestrel - IUD in the treatment of uterine myoma in Thai womenKanok Jindabanjerd
Department of Obstetric and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
J Med Assoc Thai 89:S147-51. 2006..This study was designed to evaluate the potential usefulness of the levonorgestrel-releasing intrauterine device (LNG - IUD ; Mirena) in treating women with uterine myomas...
- Effect of different contraceptive methods on the oxidative stress status in women aged 40 48 years from the ELAN study in the province of Liege, BelgiumJ Pincemail
Department of Cardiovascular Surgery, University of Liege, CHU Sart Tilman, 4000 Liege, Belgium
Hum Reprod 22:2335-43. 2007..Among conditions known to influence oxidative stress, the use of oral contraception (OC) in women has been a matter of ongoing discussion...
- Uterine ultrasonographic changes during endometriosis treatment: a comparison between levonorgestrel-releasing intrauterine devices and a gonadotropin-releasing hormone agonistLuiz Alberto Manetta
Department of Gynecology and Obstetrics, Faculty of Medicine Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
Ultrasound Med Biol 34:1914-8. 2008..In conclusion, levonorgestrel released directly onto the endometrium by the LNG-IUD induced smaller uterine changes than did the hypoestrogenism induced by GnRHa. Nevertheless, both promoted similar effects on endometrial thickness...
- The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish womenPeter Vestergaard
Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, DK 8000 Aarhus, Denmark
Contraception 78:459-64. 2008..Depot medroxyprogesterone acetate (DMPA) use may be associated with an increased risk of fractures; however, nothing is known about the risk associated with intrauterine contraceptive device (IUD) use...
- Use of the Levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish usersHusnu Gorgen
Department of Obstetrics and Gynecology, Haseki Education and Research Hospital, Istanbul, Turkey
Arch Gynecol Obstet 279:835-40. 2009..The aim of the present study was to measure the treatment of menorrhagia and health-related quality of life (QoL) in Levonorgestrel-releasing intrauterine system (LNG-IUS) in Turkish women...
- The Femilis LNG-IUS: contraceptive performance-an interim analysisDirk Wildemeersch
Outpatient Gynaecological Clinic and Training Centre, Ghent, Belgium
Eur J Contracept Reprod Health Care 14:103-10. 2009..To provide an update on the experience with the Femilis levonorgestrel-releasing intrauterine system (LNG-IUS) used for up to five years by parous and nulliparous women, particularly with regard to its contraceptive performance...
- A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as wellHeli K Lyytinen
Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, HUS, Finland
Int J Cancer 126:483-9. 2010..15; 1.72-2.68) was also associated with an increased risk. The association between HT use and the risk for breast cancer shows a large variation between various forms of HT, and also the use of LNG-IUS may carry a risk...
- The levonorgestrel intrauterine system in nulliparous womenSarah Prager
Department of Obstetrics, Gynecology and Reproductive Sciences, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
Contraception 75:S12-5. 2007..In conclusion, LNG-IUS is both safe and extremely efficacious for use in nulliparous women...
- The levonorgestrel-releasing intrauterine system and endometriosis stagingMariana Kefalás Oliveira Gomes
Department of Gynecology and Obstetrics, University of São Paulo at Ribeirão Preto School of Medicine, Ribeirao Preto, Brazil
Fertil Steril 87:1231-4. 2007..Both treatments reduced the extent of pelvic endometriotic lesions in patients with chronic pelvic pain...
- Lost levonorgestrel IUD: diagnosis and therapyShmuel Nitke
Soroka University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel
Contraception 69:289-93. 2004..Lost levonorgestrel-releasing IUDs might be found in the mid-upper abdomen, embedded in omentum tissue, and this area should be explored first during laparoscopy...
- Clinical practice. Long-acting methods of contraceptionHerbert B Peterson
Department of Maternal and Child Health, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA
N Engl J Med 353:2169-75. 2005
- Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugsWalli Bounds
Department of Obstetrics and Gynaecology, University College London and Research Co ordinator, Margaret Pyke Centre, London, UK
J Fam Plann Reprod Health Care 28:78-80. 2002..Contraception for women on enzyme-inducing drugs...
- New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiationR Sitruk-Ware
Center for Biomedical Research, Population Council and Rockefeller University, New York, NY 10021, USA
Climacteric 10:358-70. 2007..Several of these systems are either available or in development. Long-term studies on the risk/benefit of various non-oral formulations are certainly warranted...
- Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasiaAnne Beate Vereide
Department of Gynecology and Obstetrics, Institute of Clinical Medicine, Norway
Gynecol Oncol 101:214-23. 2006..The effect on progesterone and estrogen receptor expression in glands and stroma after two different treatment regimens of endometrial hyperplasia was determined...
- A comparison of oral misoprostol tablets and vaginal prostaglandin E2 pessary in induction of labour at termAnjum Ara Hassan
Department of Obstetrics and Gynaecology, Hamdard University Hospital, Karachi
J Coll Physicians Surg Pak 15:284-7. 2005..To compare the cost-effectiveness, mode of delivery, fetal and maternal outcome of oral Misoprostol and vaginal prostaglandin E2 pessary in induction of labour at term...
- VULVODYNIA PREVALENCE AND EFFICACY OF 4 INTERVENTIONSGloria Bachmann; Fiscal Year: 2004..Our ultimate goal is to share findings from this and related research with the broadest cross-spectrum of women that we can. ..
- PDE3 Inhibitors: Selective Blockers of Oocyte MaturationJeffrey Jensen; Fiscal Year: 2007..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
- Clinical Research in Human FertilityJoseph Stanford; Fiscal Year: 2005..Standford to develop his skills and gain the expertise needed to accomplish his goals. ..
- Control of menstrual bleeding disturbances in womenIan Fraser; Fiscal Year: 2006..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
- DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORSDavid Archer; Fiscal Year: 2006..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..